Overview
A Phase 2 randomized, open-label trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant in front-line non-small cell lung cancer.
Key Eligibility Criteria
clinicaltrials.gov
Overview
A randomized Phase 3, open-label, study to evaluate the efficacy of zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with domvanalimab (AB154) in front-line, PD-L1-positive locally advanced or metastatic non-small cell lung cancer.
Key Eligibility Criteria
clinicaltrials.gov
Overview
A Phase 1/1b open-label, dose-escalation and dose-expansion trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + carboplatin and pemetrexed, with or without zimberelimab in EGFR mutant non-small cell lung cancer.
Key Eligibility Criteria
clinicaltrials.gov
Healthcare Professionals: to learn more about Arcus trials, email [email protected]
Patients and Caregivers: Talk to your doctor if you are interested in learning more about Arcus clinical trials.
These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.
